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Abstract. A hierarchical mixed-effects model is proposed to account for both individual- and
population-level variability in human immunodeficiency virus (HIV) dynamics. This model is imple-
mented by formulating the crucial parameters as random variables in an in-host HIV model. Model
reduction is used to guide the choice for a minimal set of parameters, whose distributions are es-
timated by the global two-stage method. We analyze the system of ordinary differential equations
with random coefficients and provide numerical simulations illustrating its asymptotic behaviors.
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1. Introduction. There have been many mathematical models that attempt
to describe the interaction of CD4+ T-cells and the human immunodeficiency virus
(HIV) in the immune system [8, 9, 13, 19, 21]. Mathematical models can be useful
in helping to understand and predict the pathogenesis of HIV infection or to suggest
a strategy that can improve patient adherence. The studies by Perelson and Nelson
[19] demonstrate how mathematical models have revealed some important features
of HIV pathogenesis and impacted the way in which HIV patients are treated with
efficient antiretroviral drugs. Callaway and Perelson [9] investigated the ability of
several biologically motivated models of HIV infection dynamics to explain sustained
low viral loads. In [8], the authors suggested the dynamics of the immune response
with a Michaelis--Menten-type saturation nonlinearity. Incorporation of the immune
response allowed the model to exhibit transfer between unhealthy and healthy steady
states through structured treatment interruptions [2].
For our study, we adopt a simple in-host model as a reasonable approximation
of the dynamics for any specific individual. However, the dynamics for different in-
dividuals may vary because of the individual variability in viral production, immune
response, and so on. In fact, the experimental data clearly exhibit a significant vari-
ability among patients and their responses to therapy. Hellerstein et al. [12] reported
direct measurements of circulating T-cell kinetics in normal and HIV-1-infected hu-
mans where production rates of CD4+ T-cells and CD8+ T-cells vary across patients.
In [11], the authors estimated the numbers of infected CD4+ T-cells and the virus they
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could produce by quantitative technique, which showed a wide range of values. As in-
vestigated in [2], the change in infectivity rates can move the stable equilibrium point
from one associated with a high viral load to another with low viral load. Hence, the
different dynamics across subjects may be attributed to differences of several crucial
parameters. In this context, we employ hierarchical nonlinear mixed-effects (NLME)
models to account for variations at both the individual and population levels [10].
We provide a brief overview of some hierarchical NLME models in HIV pathogen-
esis studies and refer the reader to a comprehensive review paper [23] on statistical
methods in HIV modeling. Putter et al. considered a system of nonlinear differential
equations and used short-term viral-load data to estimate the distributions of param-
eters [20]. The studies by Wu and Ding [24] allow variability in drug resistance and
adherence in the presence of antiretroviral treatment. In [5], the authors considered a
model including the immune response effector and proposed a modified algorithm to
deal with the censored data. Our goal is to develop a methodology that can be used
to predict the dynamics of a new patient and to suggest efficient treatment strategies
for the individual patient. With this in mind, we build a hierarchical mixed-effects
model by estimating the distribution of parameters across the population with clinical
data sets and analyze the model.
The paper is organized as follows. The rest of this section introduces a mathemat-
ical model describing the in-host HIV infection dynamics. In section 2, a hierarchical
NLME model is adopted, and parameters at both the individual and population lev-
els are estimated. In section 3, analysis of the proposed model is performed and
simulation studies are presented to demonstrate the analytical results. Finally, some
discussions and remarks are made in section 4.
1.1. Mathematical model for in-host HIV dynamics. We develop a hi-
erarchical mixed-effects model for HIV progression based on a simple in-host HIV
infection dynamics model that involves variability among patients. The model we
use to represent the dynamics of each individual is adopted from that proposed by
Perelson et al. [1, 2, 9, 14]\left\{     
dS
dt = \lambda  - dS  - (1 - \eta )kV S
dI
dt = (1 - \eta )kV S  - \delta I
dV
dt = (1 - \epsilon )NT \delta I  - cV
(1)
with given initial values for S, I, and V at time t = t0.
This model includes the key dynamic compartments of uninfected target cells S,
infected target cells I, and free virus V . The parameter \lambda denotes the rate at which
uninfected target cells are created and d denotes the death rate of these cells. The
infection rate k represents the rate of uninfected cells infected by the virus, and \delta is the
death rate of the infected target cells. Infected cells produce NT free virus particles
during a typical target cell life span, and the virus only leaves the compartment via
natural death at rate c. The reader may refer to [1, 2, 9, 15] for a more detailed
discussion of this model.
The drug efficacy parameter \eta models a reverse-transcriptase inhibitor (RTI) that
blocks new infections, and \epsilon represents the efficacy of protease inhibitor (PI). To
specify the efficacy parameter \eta for the patients who are treated only using RTI, we
employ the value of 80\% reported and justified in the literature [9]. We assume that
the values for both efficacy parameters \eta and \epsilon to be 0.6 for each patient undergoing
multidrug therapy, similar to the total drug efficacy of 80\%. The definitions of the
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Table 1
Parameters in the in-host HIV infection model.
Parameter Description Units
\lambda Birth rate of uninfected CD4+ T-cells cells/[mm3\times day]
d Death rate of uninfected CD4+ T-cells 1/day
k Infection rate of CD4+ T-cells per virion mm3/[virions \times day]
\delta Death rate of infected CD4+ T-cells 1/day
NT Burst size (number of virions released from an infected cell) -
c Natural death rate of virus 1/day
\eta Efficacy of reverse transcriptase inhibitor -
\epsilon Efficacy of protease inhibitor -
1.2. HIV clinical data. The data employed to develop our model were col-
lected by one of the authors (Choi) from patients at Severance Hospital. The en-
semble provides partial observations that consist of measurements from the combined
compartments of uninfected and infected of CD4+ T-cells and the censored RNA viral
load measurements for 1030 patients. The measurement units of values are cells/µL
for CD4 cells and copies/mL for viral load. The clinical data differs from patient to
patient, both in duration and sampling frequency. The data set also contains pre-
scription information of drug combination in antiretroviral treatment for all patients.
The treated patients are considered to be successful if a viral load is maintained below
50 copies/mL. For some patients, viral suppression was not achieved with antiretro-
viral therapy, probably owing to poor patient adherence to drugs. Considering the
feasibility, we estimated parameters from data of 176 patients: 89 patients undergoing
multidrug therapy consisting of one or more RTIs and a protease inhibitor, and 87
patients who were treated using only RTIs.
2. Hierarchical mixed-effects model. There is a great deal of variability
among patients, and dynamics may differ due to the differing crucial parameters.
A hierarchical NLME model appears to be reasonable to explain the HIV dynamics
at both the individual and population levels. A mixed-effects model represents two
levels of variability, random variation among measurements within a given individual
(intraindividual variation) and random variation among individuals (interindividual
variation). One approach is to develop a model involving the distribution of the
individual-specific parameters across the population of patients. In particular, the
parameters in the in-host HIV infection model (1) are formulated as random variables
to account for various sources of variability contained in the clinical data.
2.1. Parameter estimation of each individual. Intraindividual and interindi-
vidual variations are accommodated within the framework of a two-stage model. In
this section, we formulate the estimation problem in the context of an in-host HIV dy-
namics model (1) to characterize the intraindividual variation. The data set includes
longitudinal measurements for a population of patients with a different number of
observations and sampling frequency. As mentioned above, a typical measurement
includes the sum of uninfected and infected CD4+ T-cell counts (S+ I) and the viral
load (V ).
It is known that the half-life of uninfected CD4+ T-cells is longer than that of
infected CD4+ T-cells [12]. That is, the death rate of infected target cells is higher
than the death rate of uninfected cells. Thus, we can convert the system (1) to a more
convenient form (2) to estimate the parameters by introducing an auxiliary parameter
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\left\{     
dS
dt = \lambda  - dS  - (1 - \eta )kV S
dI
dt = (1 - \eta )kV S  - (d+ \mu )I
dV
dt = (1 - \epsilon )NT (d+ \mu )I  - cV.
(2)
Let \~\bfittheta denote the individual-specific parameters in the model (2), and we will
use the notation \bfittheta = ln(\~\bfittheta ) as parameters in the subsequent discussions. Given the
jth measurement [S(tj) + I(tj), V (tj)]
T , j = 1, . . . , N for the individual, let \bfity j =
[log(S(tj) + I(tj)), log(V (tj))]
T . We assume a statistical model for the observations
of the form
\bfitY j = \bfitf (tj ;\bfittheta 0) + \bfitvarepsilon j , j = 1, . . . , N,
where \bfitY j is a random vector composed of the log-scaled prediction \bfitf (tj ;\bfittheta ) at tj with
true parameter \bfittheta 0 and the measurement error \bfitvarepsilon j \sim \scrN (0, V0). The log-scaled predic-
tion is generated by taking [log(S(tj) + I(tj)), log(V (tj))]
T after solving the system
of ordinary differential equations (2) for S(t), I(t) and V (t), given values of parame-





estimator \^\bfittheta and the bias-adjusted approximation for covariance \^V can be obtained
using the weighted goodness-of-fit approach [6, 22]:
\^\bfittheta = arg min
\bfittheta \in \Omega \theta 
N\sum 
j=1
[\bfity j  - \bfitf (tj ;\bfittheta )]TV  - 10 [\bfity j  - \bfitf (tj ;\bfittheta )],
\^V = diag
\left(  1
N  - \kappa \theta 
\left(  N\sum 
j=1




where \kappa \theta is the number of parameters. As \bfittheta 0 and V0 are both unknown and coupled in
the system of equations, the process is implemented iteratively to avoid computational
complexity [6]. The details are given in section 5.
We estimate the parameters of the in-host HIV progression model (2) for 176
HIV patients undergoing therapies based on partial state observations S + I and V .
The observed quantities display a high degree of interpatient variability, including
initial status and disease progression. The fitted data for two typical cases can be
viewed in Figure 1, where the solid lines represent the simulations corresponding to
the optimized parameters. Patient A with initial CD4 cell counts of 500 cells/µL was
treated and exhibited suppressed viral loads. The other patient B who was at the
AIDS stage at the beginning has reduced and maintained low viral loads due to the
treatment.
2.2. Model reduction. The parameters are formulated as random variables in
the mixed effects model to account for variability at both the individual and pop-
ulation levels. This model study requires a procedure to estimate the distribution
of parameters, which is a formidable challenge if the dimension of the parameters is
high. We employ a model-reduction technique in which the model fits the data with
a minimal set of parameters [4, 16]. In this approach, we first rank the parameters to
determine which are the most crucial to the HIV infection dynamics. Then, we use a
nested model comparison test to decide whether the data can be adequately described
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Fig. 1. The model fit (solid line) to time series data (circles) for patient A (top) and pa-
tient B (bottom). Fit of model using estimated parameters to the CD4+ T-cell counts S(t) + I(t)
(left) and viral load V (t) (right) are presented. The suppression level of viral loads (dashed line,
0.05 copies/\mu L) is also displayed for reference.
2.2.1. Parameter ranking via sensitivity analysis. We investigate the sen-
sitivity of the model with respect to parameters. The sensitivities defined by
[F (\bfittheta )]j,k =
\partial \bfitf (tj ;\bfittheta )
\partial \bfittheta k
can be computed by solving the sensitivity equations.
The order of parameters is given according to the sensitivity when the dependency
on the previous parameters was removed. This can be implemented by using a QR
decomposition of the sensitivity matrix F (\bfittheta ), whose details are given in section 5.
The results of the parameter ranking for two patients are presented in Figure 2.
2.2.2. Model comparison. Under the assumption that the measurement errors
\varepsilon j , j = 1, 2, . . . , N are normally distributed, Akaike information criterion (AIC) can
be applied in the framework of the least-squares method [6, 4, 7]






\bfity j  - \bfitf (tj ; \^\bfittheta )
\Bigr] T \Bigl[ 
\bfity j  - \bfitf (tj ; \^\bfittheta )
\Bigr] \right)  + 2(\kappa \theta + 1),
where N is the number of measurements, \nu is the dimension of measurements, and
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Fig. 2. Parameter ranking based on the orthogonalization of the sensitivity matrix for patient
A (left) and patient B (right).
complexity of model by incorporating the squared sum of errors and the dimension of
the parameters. Because AIC may perform poorly if the sample size is small relative
to the total number of estimated parameters, we use a variation suggested for small
samples [3, 6]:
AICc = AIC +
2\kappa \theta (\nu + \kappa \theta + 1)
N  - (\nu + \kappa \theta + 1)
.
To accomplish the goal to fit the data with a minimal set of parameters, we
generate nested models based on the parameter ranking for each patient. First, we
estimate only the most important parameter and fix the other parameters as the
median of individually estimates whose distributions are mostly asymmetric. Then,
we estimate the two most important parameters and repeat the process by increasing
the number of parameters to be estimated according to the ranking. Nested models
are compared using a small-sample AIC to determine the best approximating model,
which is the one with the minimum AIC. The results of the model comparison for
two patients are presented in Table 2. For the case of patient A, the parameters were
ranked in order of decreasing sensitivity, given as NT , \lambda , c, k, \delta . We determine that the
minimal set of parameters is \{ NT , \lambda , c, k\} with the minimum AIC value  - 199.7730.
Similarly, we conclude that one parameter \{ NT \} can adequately describe the data for
patient B.
Table 2
Model comparison results for patient A (left) and patient B (right).
\bfittheta AIC
NT -113.1571
NT , \lambda -110.9056
NT , \lambda , c -108.7563
NT , \lambda , c, k -199.7730
NT , \lambda , c, k, \delta -199.0503
\bfittheta AIC
NT -100.6845
NT , \lambda -96.2909
NT , \lambda , k -89.5633
NT , \lambda , k, d -80.5865
NT , \lambda , k, d, \delta -57.2201
Our goal is to reduce the number of random parameters which reflect the popula-
tion level understanding of HIV dynamics. However, the best approximating model,
or the minimal set of parameters that is sufficient to describe the data, differs from
patient to patient. We present the frequency of the selected parameters as a result of
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Table 3
Frequency of minimal set of parameters as a result of model reduction.
Minimal set of parameters Counts Minimal set of parameters Counts
NT 58 c,d,\lambda 2
c 44 NT ,d,\lambda ,k 2
k 12 c,NT ,d,\lambda 2
NT ,d,k,\lambda 5 c,NT 1
NT ,d,k 4 c,NT ,k 1
NT ,\lambda 3 d 1
c,\lambda ,k 3 c,d,NT 1
NT ,\lambda ,d 3 c,NT ,d,k 1
NT ,d,\lambda 3 k,c,NT ,d 1




and \{ c\} for 44 patients, and we determined NT and c to be formulated as random
variables.
2.3. Estimation of population parameters. After establishing the individual-
level model, we seek a population-level understanding of HIV progression. We esti-
mate the distribution of random variables across the population of patients from the
individual-specific parameter values using the global two-stage (GTS) method [10].
Let \~\bfittheta i denote the individual-specific parameters for patient i and use \bfittheta i = ln( \~\bfittheta i)
as in the previous sections. Given the measurement \~\bfity i for the ith individual, let
\bfity i = log( \~\bfity i) and let \bfitf i(\bfittheta i) denote the log-scaled model prediction, a collection of
values for all time tj with his or her parameter \bfittheta i.
Incorporating the uncertainty of estimation in \bfittheta i based on the asymptotic theory,
it is assumed that \bfittheta i \sim \scrN (\bfittheta \ast , Ci+D), such that the two-stage model may be written
as
Stage 1 (intra-individual variation)
\bfity i = \bfitf i(\bfittheta i) + \bfitvarepsilon i, \bfitvarepsilon i| \bfittheta i \sim \scrN (0, Vi)
Stage 2 (inter-individual variation)
\bfittheta i = \bfittheta 
\ast + \bfitb \bfiti + \bfite 
\ast 
i , \bfitb \bfiti \sim \scrN (0, D), \bfite \ast i \sim \scrN (0, Ci).
In implementing this algorithm, an estimate of the asymptotic covariance matrix
Ci for individual i would be used, where
Ci =
\left(  N\sum 
j=1
[Kj( \^\bfittheta \bfiti )]
T \^V  - 1[Kj( \^\bfittheta \bfiti )])
\right)   - 1 , Kj(\bfittheta \bfiti ) = \partial \bfitf (tj ;\bfittheta \bfiti )
\partial \bfittheta \bfiti 
,
and \bfittheta and D can be estimated by minimizing the negative loglikelihood
\scrL GTS(\bfittheta \ast , D) =
m\sum 
i=1
ln | Ci +D| +
m\sum 
i=1
(\bfittheta i  - \bfittheta \ast )T (Ci +D) - 1(\bfittheta i  - \bfittheta \ast ).
We apply the GTS method to estimate the distribution of parameters formulated
as random variables, and their corresponding statistical inference results are presented
in Table 4. The joint distribution and the marginal distributions are displayed for the
estimated parameters ln(NT ) and ln(c) in Figure 3. We also present the joint and
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Table 4
Statistical results for the parameters ln(NT ) and ln(c) estimated using GTS method.
Parameter Estimate
Mean ln(NT ) 3.0439
ln(c) 1.4901
Covariance (ln(NT ), ln(NT )) 4.6290
(ln(c), ln(c)) 7.0640
(ln(NT ), ln(c)) 4.3613


























Fig. 3. The joint distribution of ln(NT ) and ln(c) (top) and the corresponding marginal distri-
butions of ln(NT ) and ln(c) (bottom) obtained by applying GTS method.
3. Analysis of ordinary differential equations with random coefficients.
In this section, we carry out an analysis of the model (3) established incorporat-
ing both individual- and population-level variations via the introduction of random
parameters. Let (\Omega ,\scrF , P ) denote a complete probability space. \Omega is the set of all pos-
sible outcomes, \scrF \subset 2\Omega is the \sigma -algebra of events, and P : \scrF \rightarrow [0, 1] is a probability
measure. We formulate random variables NT (\omega ) and c(\omega ), where \omega \in \Omega .\left\{     
dS
dt = \lambda  - dS  - kV S
dI
dt = kV S  - \delta I
dV
dt = NT (\omega )\delta I  - c(\omega )V
(3)
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Fig. 4. The joint distribution of NT and c (top) and the corresponding marginal distributions
of NT and c (bottom) obtained by applying GTS method.
To ensure the nonnegativity of solutions and to analyze asymptotic behavior, we
assume that there are cmin, cmax, NTmax \in (0,\infty ) such that
cmin \leq c(\omega ) \leq cmax and NT (\omega ) \leq NTmax.(4)
For the condition (4) for NT (\omega ) and c(\omega ), as a practical example, NT and c could
have a truncated log-normal distribution.
3.1. Existence and uniqueness. The existence and uniqueness of a solution
to (3) can be obtained by applying the following theorem (see [18]).
Theorem 3.1. Consider the stochastic differential equation
d\bfitx (t) = \bfitg (t,\bfitx )dt+ \bfitsigma (t,\bfitx )dBt, t \in [0, T ],(5)
where \bfitx (0) = \bfitz is a random initial condition satisfying E
\bigl[ 




| \bfitg (t,\bfitx )| + | \bfitsigma (t,\bfitx )| \leq C(1 + | \bfitx | ) \forall \bfitx \in Rn,(6)
and
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| \bfitx (t)| 2dt
\Biggr] 
< \infty .
We now state and prove an existence and uniqueness theorem for a solution to
the system of ordinary differential equations (ODEs) with random coefficients.
Theorem 3.2. For any positive initial value, there is a unique solution to the
system of random ODEs (3).
Proof. Let \~\bfitx = [S, I, V ], and define \~\bfitg : R+ \times R3 \rightarrow R3 by
\~\bfitg (t, \~\bfitx ) =
\left[  \lambda  - dS  - kV SkV S  - \delta I
NT \delta I  - cV
\right] 
.
Then, (3) can be rewritten by \Biggl\{ 
d\~\bfitx 
dt = \~\bfitg (t, \~\bfitx ),
\~\bfitx (0) = \~\bfitx 0,
and \bfitsigma (t, \~\bfitx ) = 0.
In order to use Theorem 3.1, let \bfitx = [\~\bfitx , \bfitz (\omega )]T with a random variable \bfitz (\omega ) =
[NT (\omega ), c(\omega )]
T satisfying E
\bigl[ 
| \bfitz | 2
\bigr] 
< \infty , and let \bfitg = [\~\bfitg , 0]T . Then, consider the
augmented system \Biggl\{ 
d\bfitx 
dt = \bfitg (t,\bfitx ),
\bfitx (0) = \bfitx 0.
Note that | \~\bfitg (t,\bfitx )| = | \bfitg (t,\bfitx )| .
To verify the condition (7), we show that \~\bfitg is locally Lipschitz continuous. Be-
cause the derivative of \~\bfitg 
\nabla \~\bfitg =
\left[   - d - kV 0  - kSkV  - \delta kS
0 NT (\omega )\delta  - c(\omega )
\right]  
is continuous and locally bounded; \~\bfitg is locally Lipschitz continuous.
Now, we have
| \~\bfitg (t,\bfitx )| =
\bigm| \bigm| \bigm| \bigm| \bigm| \bigm| 
\left[  \lambda  - dS  - kV SkV S  - \delta I
NT \delta I  - cV
\right]  \bigm| \bigm| \bigm| \bigm| \bigm| \bigm| \leq 
\bigm| \bigm| \bigm| \bigm| \bigm| \bigm| 
\left[  \lambda 0
0
\right]  \bigm| \bigm| \bigm| \bigm| \bigm| \bigm| +
\bigm| \bigm| \bigm| \bigm| \bigm| \bigm| 
\left[   - dS  - kV SkV S  - \delta I
NT \delta I  - cV
\right]  \bigm| \bigm| \bigm| \bigm| \bigm| \bigm| = \lambda +
\bigm| \bigm| \bigm| \bigm| \bigm| \bigm| 
\left[   - dS  - kV SkV S  - \delta I
NT \delta I  - cV
\right]  \bigm| \bigm| \bigm| \bigm| \bigm| \bigm| .
Because \~\bfitg is locally Lipschitz continuous, there is a constant \^D such that\bigm| \bigm| \bigm| \bigm| \bigm| \bigm| 
\left[   - dS  - kV SkV S  - \delta I
NT \delta I  - cV
\right]  \bigm| \bigm| \bigm| \bigm| \bigm| \bigm| = | \~\bfitg (t,\bfitx ) - \~\bfitg (t,0)| \leq \^D| \bfitx | ,
and hence,
| \~\bfitg (t,\bfitx )| \leq \lambda + \^D| \bfitx | \leq C(1 + | \bfitx | ),
where C = max(\lambda , \^D).
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3.2. Nonnegativity. We show that the model proposed in this paper possesses
nonnegative solutions, as this is essential for the model to be biologically feasible. We
prove this positively invariant property in the following theorem.
Theorem 3.3. For any positive initial value, the solution \bfitx (t) to a random ODE
system (3) will be positive.
Proof. By Theorem 3.2, there is a unique local solution \bfitx (t) on [0, \tau e) for any
positive initial value \bfitx 0, where \tau e is the explosion time defined by (see [17])
lim
t\uparrow \tau e
| \bfitx (t)| = \infty .
To prove that the solution is global, we need to show that \tau e = \infty . Let us define the
stopping time \tau s:
\tau s = inf \{ t \in [0, \tau e) : S(t) \leq 0 or I(t) \leq 0 or V (t) \leq 0\} .
It is enough to show that \tau s = \infty to conclude the solution \bfitx (t) \in R3+ almost surely
for t \geq 0.
We assume that \tau s < \infty , which will lead to a contradiction. Define a function
\phi (\bfitx (t)) : R3+ \rightarrow R3+ by \phi (\bfitx (t)) = ln (SIV ). Then,




 - d - kV + kV S
I
 - \delta +NT (\omega )\delta 
I
V
 - c(\omega )
\biggr] 
dt.
From (4), we obtain
d\phi (\bfitx (t)) \geq [ - d - kV  - \delta  - cmax] dt.
Therefore,
\phi (\bfitx (t)) \geq \phi (\bfitx 0) - 
\int t
0
kV (s)ds - (d+ \delta + cmax)t.
Note that the right-hand side is finite for t < \tau s < \tau e. Letting t \rightarrow \tau s leads to the
contradiction
 - \infty = lim
t\rightarrow \tau s




kV (s)ds - lim
t\rightarrow \tau s
(d+ \delta + cmax)t >  - \infty .
Consequently, \tau s = \infty almost certainly.
3.3. Asymptotic behavior. In this section, we investigate the asymptotic be-
havior of solutions, which is of great interest in the study of biological systems. We
carry out analysis on the stochastic equilibrium, and the results are illustrated by nu-
merical simulations. First, we establish the conditions for extinction in the following
theorem.
Theorem 3.4. Consider the random ODE system (3) with the initial condition
in R3+. Assume that NT and c follow a multivariate truncated log-normal distribution.
If cmind - k\lambda NTmax > 0, then I(t) and V (t) tend to zero exponentially with probability
one.
Proof. The first equation of our random ODE system (3),
dS
dt
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yields









which further implies bounds on the state S,\Biggl\{ 
S(t) \leq \lambda d if S0 \leq 
\lambda 
d ,
S(t) \leq S0, otherwise.








 - \delta kS(t)







 - \delta k \cdot \lambda d






We define \bfitx = [
I
V
] and A = [  - \delta k\cdot 
\lambda 
d
NT (\omega )\delta  - c(\omega )
] to formulate a system d\bfitx dt = A\bfitx whose
solutions tend to zero exponentially with probability one.
By solving the characteristic equation
\nu 2 + (\delta + c(\omega ))\nu + c(\omega )\delta  - k\lambda 
d






 - (\delta + c(\omega )) +
\sqrt{} 
(\delta + c(\omega ))2  - 4
\biggl( 
c(\omega )\delta  - k\lambda 
d







 - (\delta + c(\omega )) - 
\sqrt{} 
(\delta + c(\omega ))2  - 4
\biggl( 
c(\omega )\delta  - k\lambda 
d
NT (\omega )\delta 
\biggr) \Biggr\} 
.
Both eigenvalues are real, and \nu 2 < 0 because
(\delta + c(\omega ))
2  - 4
\biggl( 
c(\omega )\delta  - k\lambda 
d
NT (\omega )\delta 
\biggr) 
= (\delta  - c(\omega ))2 + 4k\lambda 
d
NT (\omega )\delta > 0.
In order for \nu 1 to be negative, it is required that
c(\omega )\delta  - k\lambda 
d
NT (\omega )\delta > 0.
It then follows from the assumption (4) that
c(\omega )\delta  - k \cdot \lambda 
d
\cdot NT (\omega )\delta > cmin\delta  - k \cdot 
\lambda 
d
\cdot NTmax\delta = cmin\delta 
\biggl( 




Hence, we show that I(t) and V (t) tend to zero under the condition cmind  - 
k\lambda NTmax > 0 for case S0 \leq \lambda d . Using similar arguments, one can obtain the same
condition for extinction in the case of S0 >
\lambda 
d . Therefore, we conclude that solutions
extinct if cmind - k\lambda NTmax > 0.
According to our analytical results, both the infected cells and the virus particles
exponentially tend to zero with probability one under the conditions specified in
Theorem 3.4. The numerical simulations in Figure 5 support these results, illustrating
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Fig. 5. The trajectories (gray) of uninfected cells, infected cells, and the virus using samples
of NT and c under the condition for extinction are plotted (top). The dynamics of each state
corresponding to the mean value of NT and c are also displayed (black solid). Frequency histograms
of S, I, and V based on 100, 000 simulations at time t = 20 using sample pairs of NT and c are
shown (bottom).
and system parameters, other than NT and c, are fixed as the median of individually
estimated values; in other words, we have S(0) = 238.4283, I(0) = 2.9865, V (0) =
0.0913, \lambda = 2.3039, d = 0.0044, k = 0.0025, and \mu = 0.001. The values of NT and c
are sampled following the truncated log-normal distribution, where NTmax and cmin
are chosen to satisfy the condition cmind - k\lambda NTmax > 0. The trajectories of each state
are plotted, demonstrating that both I and V tend to zero asymptotically. Figure
5 also shows histograms of the approximate stationary distribution of the uninfected
cells, infected cells, and the virus.
We now consider a more realistic example with parameters estimated from actual
data in the previous section. That is, we keep all the parameters the same as in
Figure 5, except for those formulated as random variables to account for variability.
The joint distribution of NT and c follows the truncated distribution of multivariate
log-normal estimated using the global two-stage method. This choice of parameters
does not satisfy the condition for extinction in Theorem 3.4. Figure 6 displays both
trajectories and histograms of uninfected and infected CD4+ T-cells and viral load,
illustrating persistence. The numerical results strongly indicate that the HIV infection
model (3) has a stationary distribution, while we have not so far been able to prove
this.
4. Discussions. We have presented a hierarchical mixed-effects model to ac-
count for HIV dynamics at both the individual and population levels. A simple in-
host HIV model was adopted to represent the infection dynamics of each individual.
The crucial parameters in the model were formulated as random variables to incor-
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Fig. 6. The trajectories (gray) of uninfected cells, infected cells, and the virus using samples of
NT and c following the truncated multivariate log-normal estimated by the global two-stage method
are plotted (top). The dynamics of each state corresponding to the mean value of NT and c are also
displayed (black solid). Frequency histograms of S, I, and V based on 100, 000 simulations at time
t = 20 using sample pairs of NT and c are shown (bottom).
parameter values and the distribution of random variables were estimated using the
field data of 176 patients. We have also analyzed the proposed model with random
inputs, showing the existence, uniqueness, and nonnegativity of the solutions. Then,
we investigated asymptotic behaviors and established conditions for the extinction of
a disease. Finally, numerical simulations exhibit the stationary distribution of both
extinction and persistence cases.
The eventual goal of our research is to predict the future patterns of the response
at each individual, taking uncertainty and population level variability into consider-
ation. It will allow one to design different individual therapy regimes and to suggest
best performance treatment strategies. This paper is only a first step in developing
mixed effects models, which can be used to achieve eventual aims of prediction and
control. One may study a more realistic version by improving several ways such as
employing advanced parameter estimation techniques and researching on the efficacy
of drug cocktails. We have left these for further investigations.
5. Appendix.
5.1. Parameter and covariance estimation. Let \^\bfittheta denote the estimated pa-
rameter obtained by solving the problem
\^\bfittheta = arg min
\bfittheta \in \Omega \theta 
N\sum 
j=1
[\bfity j  - \bfitf (tj ;\bfittheta )]T \^V  - 1[\bfity j  - \bfitf (tj ;\bfittheta )],(8)
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It can be approximated by \^V in the following formula:
V0 \approx \^V = diag
\left(  1
N  - \kappa \theta 
\left(  N\sum 
j=1




where N is the number of measurement, \kappa \theta is the number of parameters, and \^\bfittheta is a
parameter estimator. However, \^V and \^\bfittheta are coupled in the sense that computing \^V
in (9) involves \^\bfittheta and estimating \^\bfittheta in (8) requires V0.
We follow a standard practice of decoupling at a cost of iteration to take care of
this coupled problem, which can be implemented as
1. Choose an initial guess for \^V as \^V (0) = \bfitI and estimate \^\bfittheta 
(0)
by the formula
(8) and set l = 0.
2. Evaluate \^V (l+1) with \^\bfittheta 
(l)
using (9).
3. Update \^\bfittheta from (8) with \^V = \^V (l+1) to obtain \^\bfittheta 
(l+1)
.
4. Set l = l + 1 and return to step 2 until two successive estimates of iteration
for \^\bfittheta are close enough.
As a result of this iterative process, we obtain both estimates \^\theta and \^V .
5.2. Solving sensitivity equation. Let \bfitf (tj ;\bfittheta ) = [f1(tj ;\bfittheta ), f2(tj ;\bfittheta )]
T =
[log(S(tj)+ I(tj)), log(V (tj))]
T be the log-scaled prediction and define the sensitivity
matrix as follows:
F (\bfittheta ) =

















\partial f1(tN ;\bfittheta )
\partial \lambda 
\partial f1(tN ;\bfittheta )
\partial d \cdot \cdot \cdot 


















\partial f2(tN ;\bfittheta )
\partial \lambda 
\partial f2(tN ;\bfittheta )
\partial d \cdot \cdot \cdot 
\partial f2(tN ;\bfittheta )
\partial NT
\right]                
.
It tells us how much the prediction changes as each parameter \theta k perturbs (k =
1, 2, . . . , \kappa \theta ).
Among several ways to compute this sensitivity matrix F (\bfittheta ) ([6, see Chapter 3]),




\approx f(tj ;\bfittheta + \bfith 1) - f(tj ;\bfittheta )
\| \bfith 1\| 
,
where \| \cdot \| is the Euclidean norm in \kappa \theta -dimensional real vector space \bfitR \kappa \theta and \bfith 1
is a \kappa \theta \times 1 vector whose entries are 0, except that the first one is chosen as a very
small value. Here, each parameter is perturbed by 1\% of it estimated value (i.e.,
\bfith 1 = [0.01 \ast \lambda , 0, . . . , 0]T ).
Based on this sensitivity matrix F (\bfittheta ), parameters are ranked by the following
process. Note that the kth column of F (\bfittheta ) is a sensitivity vector for the parameter
\theta k, all parameters are in log-scale, and L2-norm is used to measure a vector. We
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the one with the largest norm as the 1st because the larger norm represents the bigger
impact on the dynamics. In Figure 2, ln(NT ) rank the 1st for both Patient A and
Patient B. Then, we orthogonalize the remaining sensitivity vectors by removing the
1st-ranked direction and compare the norm of the resulting vectors to determine the
2nd one attaining the largest norm. The 2nd ranked parameter is ln(\lambda ) for Patient A
and Patient B, in Figure 2. The direction of 2nd-ranked sensitivity vector is removed
from the remaining vectors, select the 3rd parameter and repeat this process until all
the parameters are ranked.
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